Log in to search using one of your social media accounts:

 

Arsenic Overcomes Retinoic Acid-Resistance Conferred by FLT3-ITD in a Mouse Model of Acute Promyelocytic Leukemia (APL)
Experiments in mouse models have demonstrated that PML/RARA degradation is primary to the cure of APL with retinoic acid (RA) or arsenic (As). FLT3-ITD mutation occurs in 40% of APL cases and may confer a poorer prognosis. Reports suggest that adding As to patients ’ treatment may abrogate this adverse effect. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Ramy Rahm é, Cécile Esnault, Hugues de Thé Source Type: research

Results of Second Salvage Therapy for Acute Myeloid Leukemia in the Modern Era
Most published studies analyze the results of salvage therapies in primary refractory or first salvage (S1) AML patients only. Several novel agents and strategies are under evaluation for potential approval in the second-salvage (S2) setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Aron Simkins, Courtney D. DiNardo, Tapan Kadia, Naval Daver, Naveen Pemmaraju, Kiran Naqvi, Maro Ohanian, Koichi Takahashi, Yesid Alvarado, Mark Brandt, Sherry Pierce, Marina Konopleva, Elias Jabbour, Guillermo Garcia-Manero, Jorge Cortes, Farhad Ravandi- Source Type: research

Diagnostic and Prognostic Value of CD123 in Acute Myeloid Leukemia (AML)
Recent studies indicate that abnormalities of the alpha-chain of the interleukin-3 receptor (IL-3RA or CD123) are frequently observed in some leukemic disorders and may contribute to the proliferative character of leukemic cells. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Taghreed Kamal Eldin, Eman M. Nagiub Abdelsalam, Ghadeer Abdel Razek, Howaida Nafady, Mostafa F. Mohammed Saleh Source Type: research

Combinatorial Targeting of Leukemia and Stromal Cells Overcomes Fms-like Tyrosine Kinase 3 (FLT3) Inhibitor Resistance in Acute Myeloid Leukemia (AML)
AML, FLT3-ITD, dual MEK1-FLT3 inhibitor, peptidic CXCR4-antagonist, leukemia-stroma interactions (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Seemana Bhattacharya, Hong Mu, Sujan Piya, Weiguo Zhang, Teresa McQueen, Linda Paradiso, Galia Oberkovitz, Eyal Benami, Michael Andreeff, Gautam Borthakur Source Type: research

Genomic Landscape of Mixed Phenotype Acute Leukemia (MPAL)
Mixed phenotype acute leukemia (MPAL) is a rare subgroup of acute leukemia characterized by blasts that show immunophenotypes of both myeloid and lymphoid lineages. It poses significant diagnostic and therapeutic challenges in clinic, yet genetic basis of MPAL is not well understood. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Kiyomi Morita, Feng Wang, Keyur Patel, Carlos Bueso-Ramos, Abdallah Abou Zhar, Curtis Gumbs, Latasha Little, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Jianhua Zhang, Xingzhi Song, Marisela Mendoza, Chang-Jiun Wu, Steven Kornblau, Courtney DiNardo, Source Type: research

CG ′806, a First-in-Class FLT3/BTK Inhibitor, Exerts Superior Potency against AML Cells Harboring ITD, TKD and Gatekeeper Mutated FLT3 or Wild-Type FLT3
FLT3 is widely accepted as a prime target for acute myeloid leukemia (AML) therapy. However, targeted therapy using current available FLT3 inhibitors only achieved limited clinical efficacy in mono-therapy. Acquired mutations of FLT3, including D835 or “gatekeeper” F691 mutations, have been identified in clinical patients who showed resistance/relapse to the inhibitors. CG’806 is a small molecule multi-kinase inhibitor against FLT3 and BTK kinases that is under development to treat FLT3-driven AML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Weiguo Zhang, Hongying Zhang, Andrea Local, Wiliam Rice, Charlie Ly, Guopan Yu, Stephen Howell, Michael Andreeff Source Type: research

Defining Acute Myeloid Leukemia Ontogeny in Older Patients
The primary objective of this study was to validate the use of somatic mutations to determine AML ontogeny in the elderly population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Megan Melody, David Sallman, Najla AlAli, Hanadi Ramadan, Ling Zhang, Eric Padron, Kendra Sweet, Martine Extermann, Alan List, Jeffery Lancet, Rami Komrokji Source Type: research

Survival Time is Problematic as an Indicator of an anti- AML Drug ’s Effectiveness
“Complete response” (CR) in AML was originally recognized as a distinct response when because people who met the criteria for CR (ANC> 1,000, platelet count> 100,000, marrow with (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Carole Shaw, Shelly Hager, Mary-Elizabeth Percival, Roland Walter, Pamela Becker, Kathleen Shannon-Dorcy, Elihu Estey, Kelda Gardner Source Type: research

Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Hematopoietic Stem Cell Transplantation (HSCT): Final Data from an Expanded-Access Protocol
VOD/SOS is an unpredictable, potentially life-threatening complication of conditioning regimens for HSCT; VOD/SOS with multi-organ dysfunction (MOD) may be associated with>80% mortality. Defibrotide is approved to treat hepatic VOD/SOS with renal/pulmonary dysfunction post-HSCT in the US and to treat severe hepatic VOD/SOS post-HSCT in the EU. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Paul Richardson, Angela Smith, Joseph Antin, Leslie Lehmann, Sergio Giralt, Wei Liang, Robin Hume, William Tappe, Nancy Kernan Source Type: research

Day+100 Survival and Safety Results from a Defibrotide Expanded-Access Program for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): Final Results
VOD/SOS is a potentially life-threatening complication of hematopoietic stem cell transplant (HSCT) conditioning or chemotherapy; VOD/SOS with multi-organ dysfunction (MOD) may be associated with>80% mortality. Defibrotide is approved for treating hepatic VOD/SOS with renal/pulmonary dysfunction post-HSCT in the US, and for treating severe hepatic VOD/SOS post-HSCT in the EU. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Nancy Kernan, Angela Smith, Joseph Antin, Leslie Lehmann, Sergio Giralt, Robert Ryan, Robin Hume, William Tappe, Paul Richardson Source Type: research

Trial in Progress: A Phase I/II Study of Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia
Lintuzumab-Ac225 is a radioimmunoconjugate composed of 225Ac (t ½=10 days), which emits 4 α-particles, linked to a humanized anti-CD33 monoclonal antibody. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Joseph G. Jurcic, Moshe Levy, Jae Park, Farhad Ravandi, Alexander Perl, John Pagel, B. Douglas Smith, Johnnie Orozco, Elihu Estey, Hagop Kantarjian, David Scheinberg, Laura Finn, Sharif Khan, Gerhard Hildebrandt, Michael Craig, Ehab Atallah, Irma Molina, Source Type: research

Acute Anthracycline Induced Cardiotoxicity in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation
Anthracyclines remain the cornerstone of therapy for a wide spectrum of malignancies and have markedly improved survival of patients with acute myeloid leukemia (AML). There is scarce data regarding the acute cardiotoxic effects of anthracyclines in AML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Oren Pasvolsky, Olga Morelli, Uri Rozovski, Moti Vaturi, Ofir Wolach, Irina Amitai, Iuliana Vaxman, Roy Ratzon, Moshe Yeshurun, Zaza Iakobishvilli, Ran Kornowski, Pia Raanani Source Type: research

MRD Status and its Prognostic Significance in High-Risk AML Patients: A Single Center Experience
Minimal residual disease plays a pivotal role in clinical decision-making and treatment tailoring in acute lymphoblastic leukemia1. Conversely, the prognostic significance of MRD and its clinical usefulness in the management of acute myeloid leukemia patients is still debated. While MRD status seems to add clinically useful information in favorable and intermediate-risk patients2, its role in high cytogenetic risk patients is much less defined. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Matteo Piccini, Arianna Fani Source Type: research

Phase 2, Randomized, Double-Blind, Placebo Controlled Study of Inecaclcitol Combined with Decitabine versus Decitabine: A New Treatment Strategy for Elderly AML Patients Unfit for Intensive Chemotherapy
Leukemogenesis is a multistep process with mutations conferring an advantage in proliferation and others leading to a blockade of maturation. Available treatments are targeting proliferation. Vitamine D is a differentiating agent acting through the Vitamin-D Receptor (VDR). AML patients ’ prognosis is correlated to VDR expression. Promoter of VDR is highly methylatded in AML cells and limits transcriptional responsiveness of VDR. This could explain the disappointing results from previous clinical trials of vitamin D. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Olivier Hermine, Jean Francois Dufour-Lamartinie, Stephanie Renaux, Jorge Cortes Source Type: research

Aqueous Urtica Dioica Leaves Extract Inhibits Proliferation of Acute Myeloid Leukemia Cells in Vitro
AML, considered as the most common type of leukemia, is characterized by the dysregulation between alive and dead cells, due to either alteration in tumor suppressor genes or activation of oncogenes, resulting in the accumulation of immature cells in the bone marrow. Urtica dioica (UD) is known to have various pharmacological activities as anti-bacterial, anti-inflammatory and anti-cancerous. The aim of this study is to examine the effect of aqueous leaves extract on the proliferation of U937 cell line. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Sandra Rizk, Nour Al Bast, Mohammad H. Hodroj, Jamilah Borjac Source Type: research

Receipt of Initial Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia (AML)
The use of chemotherapy can improve quality of life and survival in AML; however, many newly diagnosed patients do not receive any chemotherapy. Non-biological factors may influence the utilization of chemotherapy and can impact quality of care. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Vijaya Bhatt, Valerie Shostrom, Krishna Gundabolu Source Type: research

A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated On versus Off Study
Participation in clinical trials is recommended for patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) who are treated with intensive induction therapy, but enrollment is often challenging. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Mary-Elizabeth Percival, Sarah Buckley, Megan Othus, Anna Halpern, Emily Huebner, Pamela Becker, Carole Shaw, Mazyar Shadman, Roland Walter, Elihu Estey Source Type: research

Detection of Leukemia-Associated Immunophenotypic Profiles at Variable Frequencies in Healthy Donors Bone Marrow Specimens
The identification of leukemia-specific immunophenotypic profiles (LAIPs) constitutes the fundament of minimal residual disease monitoring by flow-cytometry in acute myeloid leukemia. Such MRD monitoring strategy is applicable to virtually all AML patients with satisfactory sensibility (up to 10-4) but requires a high degree of expertise. Moreover, the actual leukemia-specificity of LAIPs has never been systematically questioned. We tried to address this issue by performing a comprehensive LAIP screening in bone marrow specimens from 12 healthy controls. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Matteo Piccini, Arianna Fani Source Type: research

Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models
In this study, we evaluated the anti-leukemia effects of concomitant BCL-2 and MAPK blockade by venetoclax in combination with MEK1/2 inhibitor GDC-0973 (cobimetinib). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Lina Han, Qi Zhang, Ce Shi, Antonio Cavazos, Vivian R. Ruvolo, Joel D. Leverson, Monique Dail, Darren C. Phillips, Jun Chen, Sha S. Jin, Rodrigo Jacamo, Naval Daver, Elias Jabbour, Hagop M. Kantarjian, Michael Andreeff, Deepak Sampath, Marina Konopleva Source Type: research

Age Does Not Adversely Influence Outcomes among Patients Older than 60 Years Who Undergo Allogeneic Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Allogeneic hematopoietic stem cell transplantation (AHSCT) is a successful treatment modality for AML and MDS. Information on transplant outcomes among older patients is limited because of concern of adverse transplant-related mortality (TRM) and poor overall survival (OS). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Dipenkumar Modi, Abhinav Deol, Seongho Kim, Lois Ayash, Asif Alavi, Marie Ventimiglia, Divaya Bhutani, Voravit Ratanatharathorn, Joseph Uberti Source Type: research

Treatment Outcomes in Adults with Acute Myeloid Leukemia (AML) Using Standard Induction “3+7”, Hypomethylating Agents or Best Supportive Care: A Single Institution Experience
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with diverse genomic aberrations, treatment approaches and outcomes. Anthracycline plus cytarabine remains standard of care in fit patients; hypomethylating agents or supportive care has been suggested for elderly and those with poor performance status. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Bolanle Gbadamosi, Sanjog Bastola, Hong Ye, Daniel Ezekwudo, Foluso Ogunleye, Zhou Yu, Thomas Fennell, Erika Mora, Brian Hart, Susanna Gaikazian, Ishmael Jaiyesimi Source Type: research

Evaluating Treatment Patterns of Relapsed Acute Myeloid Leukemia Among the Elderly in the United States
The type and place of treatment for relapsed acute myeloid leukemia (AML) has not been explored in a large national population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Qisu Zhang, Lin Xie, Onur Baser, Michael McGuire Source Type: research

Sequential Treatment with FLAG-IDA Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapse/Refractory or Adverse-Risk Leukemia
Patients with relapse/refractory or adverse-risk leukemia have dismal prognosis with current therapeutic approaches. Salvage chemotherapy followed by allogeneic hematopoietic stem-cell transplantation (HSCT) is advisable but not always attainable due to disease resistance and the toxicity associated with current salvage approaches. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Ofir Wolach, Liat Shargian-Alon, Pia Raanani, Moshe Yeshurun Source Type: research

Upregulation of MCL-1 through MAPK Activation Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML
In this study, we investigated mechanisms of acquired resistance to venetoclax in preclinical AML models. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Qi Zhang, Lina Han, Ce Shi, Rodrigo Jacamo, Rongqing Pan, Ma Man Chun John, Ryan Jeremy, Stephen Kurtz, Hong Mu, Vivian Ruvolo, Helen Ma, Michael Andreeff, Yingchang Mi, Jeferrey Tyner, Joel Leverson, Anthony Letai, Richard Eric Davis, Marina Konopleva Source Type: research

GLS Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth when Combined with 5-Azacitidine
In this study we studied metabolic and cellular consequences of GLS inhibition in AML cells. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Tianyu Cai, Philip Lorenzi, Dinesh Rakheja, Michael Pontikos, Alessia Lodi, Lina Han, Qi Zhang, Helen Ma, Mohamed Rahmani, Tushar Bhagat, Thomas Horvath, Courtney DiNardo, Steven Grant, Stefano Tiziani, Amit Verma, Marina Konopleva Source Type: research

Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)
FLT3+ AML patients (prevalence 20%-30% in adult AML) often have rapid post-induction relapse, highlighting the need for new therapies. CPX-351 is a dual-drug liposomal encapsulation that delivers a synergistic ratio of cytarabine:daunorubicin. CPX-351 demonstrated significantly improved OS versus 7+3 in a phase 3 study in older adults with untreated high-risk AML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Bruno Medeiros, Donna Hogge, Laura Newell, Dale Bixby, Scott Solomon, Stephen Strickland, Tara Lin, Harry Erba, Bayard Powell, Nikolai Podoltsev, Robert Ryan, Michael Chiarella, Arthur Louie, Jeffrey Lancet Source Type: research

Central Nervous System Myeloid Sarcoma: Time for a New Approach?
Myeloid sarcoma (MS) is a rare extramedullary manifestation of acute leukemia. While it can involve any anatomic site, occurrence in the central nervous system (CNS) is uncommon and poses a diagnostic and management challenge. Owing to its rarity, therapeutic strategies remain individualized. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Tugce Akcan, Zeyad Kanaan, Adan Rios Source Type: research

Overall Survival (OS) by Outpatient versus Inpatient Consolidation in a Phase 3 Study of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)
The CPX-351 dual-drug liposomal encapsulation delivers a synergistic 5:1 molar ratio of cytarabine:daunorubicin preferentially to leukemia cells. CPX-351 demonstrated significantly improved OS versus 7+3 in a phase 3 study in older adults with newly diagnosed, secondary or high-risk AML. Standard-of-care 7+3 includes multiple-day cytarabine continuous infusion; in contrast, CPX-351 is given as a 90-minute infusion on Days 1, 3, and 5 and has the potential for outpatient administration. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jonathan Kolitz, Stephen Strickland, Jorge Cortes, Donna Hogge, Jeffrey Lancet, Stuart Goldberg, Karen Chung, Robert Ryan, Michael Chiarella, Arthur Louie, Robert Stuart, Bruno Medeiros Source Type: research

Efficacy and Safety of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (tAML): Subgroup Analysis of a Phase 3 Study
tAML may occur as a complication of cytotoxic chemotherapy/radiation and is associated with a poor prognosis. CPX-351 is a dual-drug liposomal encapsulation that delivers a synergistic ratio of cytarabine:daunorubicin. In a phase 3 trial in older adults with untreated secondary AML (tAML or with antecedent MDS), CPX-351 significantly improved overall survival (OS) versus 7+3. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jeffrey Lancet, David Rizzieri, Gary Schiller, Robert Stuart, Jonathan Kolitz, Scott Solomon, Laura Newell, Harry Erba, Geoffrey Uy, Robert Ryan, Michael Chiarella, Arthur Louie, Jorge Cortes Source Type: research

Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center Experience
High-risk AML (HR-AML), defined as AML with poor cytogenetics, antecedent hematologic disorders, and/or prior myelotoxic therapies, is associated with poor prognosis. Hypomethylating agents (HMA) are often used as an alternative induction regimen in older pts. However it is largely unknown how effective HMA fare against IC in HR-AML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Pankit Vachhani, Raed Al Yacoub, Austin Miller, Tara Cronin, Evelena Ontiveros, James Thompson, Elizabeth Griffiths, Eunice Wang Source Type: research

Assessing Selection Bias in the Assignment to Investigational Acute Myeloid Leukemia (AML) Therapy
Randomized trials are the best way to avoid bias. However the proportion of patients who are considered for randomization, but are not randomized, is rarely reported. Without this knowledge the ability to generalize results of a randomized trial to a larger population is limited. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Kelda Gardner, Mary-Beth Percival, Pamela Becker, Roland Walter, Paul Hendrie, Carole Shaw, Tejaswini Dhawale, Anna Halpern, Bart Scott, Anna Rosen, Karen Schiavo, Gabe Zecha, Andrea Perdue, Heather Smith, Alisyn Davis, Amy Kjeldahl, Elihu Estey Source Type: research

Integrating a Telemonitoring Device into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS): A Randomized Pilot Study
There is an ongoing effort towards shifting care to the outpatient setting following intensive chemotherapy for high-grade myeloid neoplasms, which is medically and logistically challenging for healthcare professionals, patients and caregivers. We hypothesize that in-home ( “telemonitoring”) devices which record vital signs, not previously tested in AML, may facilitate this approach. In this pilot study, we assessed how these devices can be integrated into the outpatient care of AML/MDS patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Anna Halpern, Utkarsh Acharya, Emily Huebner, Kelda Gardner, Roland Walter Source Type: research

Haploidentical SCT in patients with high risk AML: experience of one center.
Patients with high risk AML have short duration of remission. Availability of a donor is “corner stone” for best transplant results. Median time for activation a donor from the international register is several months. Choosing a haploidentical donor could be good alternative when matched related donor is unavailable and waiting for MUD too long. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Dmitriy Motorin, Renat Badaev, Darina Zammoeva, Larisa Girshova, Diana Babenetskaya, Natalya Ilyina, Tatyana Silina, Yuliya Alexeeva, Vladimir Ivanov, Andrey Zaritskiy Source Type: research

Phosphoinositide 3-kinase inhibitors, including idelalisib, overcome P-glycoprotein-mediated resistance to gemtuzumab ozogamicin in human acute myeloid leukemia cells
Gemtuzumab ozogamicin (GO) is a CD33 antibody-drug conjugate effective alone or in combination with other agents in a subset of patients with acute myeloid leukemia (AML). However, many patients do not benefit from GO. Though GO resistance is incompletely understood, previous studies have suggested that pro-survival signaling via AKT and activity of ABC transporters such as P-glycoprotein (Pgp) may contribute. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Colin Godwin, Olivia Bates, George Laszlo, Roland Walter Source Type: research

MRD Level in NPM1 Mutated and RUNX1-RUNX1T1 Positive AML Predicts RFS and Defines Indications for ASCT
NPM1 mutation and leukemia-specific fusion transcript RUNX1-RUNX1T1 are the predictors of favorable prognosis (DFS and OS). Nevertheless, a substantial proportion of this patients show disease relapses. It is necessary to identify negative prognostic factors for pts with NPM1mut and RUNX1-RUNX1T1 and evaluate if ASCT could overcome them. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Larisa Girshova, Irina Budaeva, Sergey Kuzin, Ekaterina Ovsiannikova, Konstantin Bogdanov, Tatjana Nikulina, Julia Mirolyubova, Dmitriy Motorin, Andrey Zaritskey Source Type: research

Stroma-Free Long-Term Growth of Primary Acute Myeloid Leukemia (AML) Cells
To individualize therapy for relapsed/refractory AML patients, robust in-vitro culture conditions to support primary leukemic cells are essential for drug sensitivity testing. Our lab has validated a high throughput chemosensitivity assay with primary AML cells maintained by cytokines; however, cytokines have not been shown to support long-term assays of primary AML cells. Stromal cells of the tumor microenvironment are also known to support survival of AML cells and influence their response to chemotherapy agents. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jing Chen, Paul Calder, Glorymar Ibanez-Sanchez, Mark Frattini Source Type: research

Post-Induction Evaluation of Acute Myeloid Leukemia Patients: The Significance of Disease Status at Day 21
Interim disease evaluation during induction chemotherapy for patients with acute myeloid leukemia (AML) remains controversial. It has been suggested that failure to achieve complete remission at day 21 is associated with a poor prognosis. Nonetheless, the significance of persistent disease and the need for an early double induction is questionable. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Nour Moukalled, Radwan Massoud, Rami Mahfouz, Zaher Chakhchiro, Samer Nassif, Jean El-Cheikh, Ali Bazarbachi Source Type: research

Incidence and Outcomes of Acute Myeloid Leukemia (AML) with Myelodysplasia (MDS) Related Changes in the United States
Leukemia, myelodysplasia, incidence, survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Guru Subramanian Guru Murthy, Ehab Atallah, Karen Carlson, Laura Michaelis Source Type: research

Feasibility of Delivery of Oral Arsenic Trioxide in Frontline therapy for Acute Promyelocytic Leukemia: A Prospective Costa Rican Study
Acute Promyelocytic Leukemia, oral Arsenic Trioxide, ATRA, Front line therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Mariela Rodriguez, Ronald Rojas, Juliana Esquivel, Claudia Garc ía, Miguel Rodríguez, Pilar Chaverri, Irma Tello, Willem Bujan Source Type: research

Improved Responses with Azacitidine Compared to Decitabine in Patients with Acute Myeloid Leukemia in Patients ≥70 with Poor-Risk Cytogenetics
Therapeutic options for patients age ≥70 years with acute myeloid leukemia (AML) are extremely limited and comprise mainly of clinical trials and hypomethylating agents (HMAs) including azacitidine (AZA) and decitabine (DEC). Thus we aim to explore clinical outcomes when treated with AZA compared to DEC. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Chetasi Talati, Andrew Kuykendall, Najla Al-Ali, Rami Komrokji, Eric Padron, David Sallman, Alan List, Kendra Sweet, Martine Extermann, Jeffrey Lancet Source Type: research

Acute Leukemia Induction Related Mortality: 6-Y Experience of Saudi Tertiary Care Institute
Mortality during induction therapy for acute leukemia, is a multifactorial process resulting in early treatment failure. It had shown sharp decline in the past 20 years in the Western world compared with developing countries. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Amal Alabdulwahab, Hussein Elsayed, Mohamed Sherisher, Khaleeq Unnisa, Ahmed Zeeneldin Source Type: research

Clinical Observations of AML Expressing Mutant RUNX1 and Pre-Clinical Studies of RUNX1-Targeted Novel Therapy of AML.
RUNX1, BRD4, BETP-PROTAC (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Courtney DiNardo, Christopher Mill, Warren Fiskus, Dyana Saenz, Agnieszka Nowak, Baohua Sun, Keyur Patel, Tapan Kadia, Christopher Benton, Koichi Takahashi, Hagop Kantarjian, Kapil Bhalla Source Type: research

Survival Impact of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive (Ph+) de novo Acute Myeloid Leukemia (AML)
Ph+ de novo AML is a rare and lethal entity conventionally requiring allogeneic stem cell transplantation as the only curative measure. TKIs have been shown to be effective in Ph+ AML. However, the impact on survival and durability of response in this high-risk population remains unclear. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Onyee Chan, Seongseok Yun, Anna Halpern, Hani Babiker, Srinath Sundararajan, Jorge Ramos, Paul Hendrie, Utkarsh Acharya Source Type: research

Novel Complex I inhibitor IACS-010759 Targets Leukemia Initiating Cells (LICs) in AML Patients
Metabolic alterations in cancer have attracted interest as a therapeutic target. Recent studies showed that leukemia initiating cells (LICs) are highly dependent on oxidative phosphorylation (OxPhos). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Natalia Baran, Lina Han, Shelley Herbrich, Shannon Renee Sweeney, Alessia Lodi, Jason Gay, Ningping Feng, Jennifer R. Molina, Marcin Kaminski, Monica L. Guzman, Gheath Al-Atrash, Stefano Tiziani, Joseph R. Marszalek, Marina Konopleva Source Type: research

Clofarabine and Low-Dose Cytarabine Combination in Relapsed/Refractory Acute Myeloid Leukemia Patients with High Risk Features
leukemia, AML, combination therapy, clofarabine, high risk. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Carlos Vigil, Nusrat Jahan, Oana Paun, Jennifer Weis, Kevin Heckman, Margarida Silverman, Thomas Carter Source Type: research

Prognostic Impact of Positive Direct Coombs Test in Chronic Lymphocytic Leukemia (CLL)
In developing countries, access to molecular prognostic markers of CLL as IgHV mutation status is restricted by limited financial resources, looking for simple prognostic markers could help in decision making and patient counseling. The clinical course of patients with B-cell CLL is often complicated by autoimmune phenomena. Positive direct coombs test as indicator of autoimmune hemolytic anemia could benefit in this issue. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Mostafa F. Mohammed Saleh, Shimaa Abdelallah, Mai M. Aly, Ghada Elsayed, Yomna Refaat, Nourhan Taleb, Asma Nady, Maha Abdel Aziz, Eman M. Nagiub Abdelsalam Tags: Chronic Lymphocytic Leukemia Source Type: research

Chronic Lymphocytic Leukemia in Brazil: Analysis of 1903 Cases
The clinical course of chronic lymphocytic leukemia (CLL) in a multicultural developing country with economical and health inequalities, such as Brazil, has not been accurately determined. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Matheus Goncalves, Celso Arrais Rodrigues, Irene Lorand-Metze, Marcelo de Lacerda, Maria de Lourdes Chauffaille, Alita Azevedo, Cintia Machado, Carlos Chiattone, S érgio Fortier, Leila Perobelli, Maura Rosane Ikoma, Nelma Clementino, Nelson Hamerschlak, Source Type: research

Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia
Eradication of residual disease is an important endpoint in patients with chronic lymphocytic leukemia (CLL), as it prolongs remission duration after chemoimmunotherapy. We conducted a phase 2 study to evaluate the efficacy and toxicity of lenalidomide given as consolidation therapy in patients with CLL who had residual disease after chemoimmunotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Paolo Strati, Michael Keating, Jan Burger, Susan O'Brien, William Wierda, Zeev Estrov, Gracy Zacharian, Alessandra Ferrajoli Source Type: research

Risk of Hospitalizations Following Initiation of Frontline Therapy in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Although several approved novel therapies have substantially changed the landscape of therapeutic choices for patients with CLL/SLL in the frontline setting, no real-world studies are available to quantify the impact of individual frontline therapies on risk of subsequent hospitalizations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Anthony Mato, Jennifer Lin, Siddhant Deshmukh, Song Wang Source Type: research

Diversity of TP53 Mutations in CLL: Retrospective Analysis of 450 Mutations from the French Innovative Leukemia Organization (FILO) Group
In CLL, TP53 mutations are associated with adverse prognosis and chemotherapy resistance. Little is known on the functional effect of the various alterations and of their associations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Myriam Hormi, Fanny Baran-Marszak, Lauren V éronèse, Pierre Sujobert, Frederic Davi, Stéphanie Poulain, Marie-Hélène Estienne, Audrey Bidet, Eric Delabesse, Stéphane Giraudier, Cédric Pastoret, Pascale Cornillet-Lefebvre, Sophy Laibe, Laurence Lode Source Type: research